排序方式: 共有121条查询结果,搜索用时 31 毫秒
1.
吸收强度涨落调制成像(AIFM)方法是基于血红细胞和背景组织对低相干光照明的吸收差异,通过在频域分离动态的血红细胞信号和静态的背景信号,实现对近透明活体生物样本全场无标记的光学血管造影成像. 但此成像方法需采集较长的原始图像序列,系统漂移或生物抖动会造成图像模糊,难以实现对某些特定区域的血管造影成像. 本文提出一种结合AIFM成像和归一化互相关算法的新方法来提升血管造影图像的质量:原始的图像序列被分成若干短时序列,每个短时序列先利用AIFM成像算法重构得到全场的血管造影图像;再利用归一化的互相关算法将所有的短时重构图像与第一帧重构图像相匹配,并融合得到最终的血管造影片. 我们以活体鸡蛋胚胎为样品,通过实验验证了利用短时归一化互相关AIFM成像方法,能够消除鸡胚胎心跳引起的图像模糊,从而获得高分辨率和信噪比的心血管造影片,对研究活体动物心脑血管疾病具有重要应用价值. 相似文献
2.
3.
【目的】研究天蚕素A-马盖宁杂合肽对耐甲氧西林金黄色葡萄球菌(MRSA)DNA作用的抑菌机制。【方法】利用激光扫描共聚焦显微镜(CLSM)、凝胶阻滞分析、紫外光谱分析、荧光光谱分析的方法。【结果】天蚕素A-马盖宁杂合肽对MRSA的最小抑菌浓度(MIC)为64 mg/L,杂合肽可以在细菌胞内形成累积,并能与体外基因组DNA发生结合作用。同时杂合肽可以引起DNA构象的改变,荧光光谱分析结果表明杂合肽能与溴化乙锭(EB)竞争性地嵌入基因组DNA中,作用方式类似于EB与DNA的结合方式,杂合肽与DNA的结合表现为混合式作用方式。【结论】天蚕素A-马盖宁进入细菌胞内,与MRSA基因组DNA结合,并以混合式作用方式与DNA发生了结合,通过胞内靶向机制发挥抑菌作用。 相似文献
4.
长非编码RNA KCNQ1OT1在多种肿瘤中高表达,但是在胃癌中的研究较少并且研究结果不一致,其在胃癌中具体的作用机制也缺乏相关研究。通过癌症基因组图谱(The Cancer Genome Atlas, TCGA)公共数据库分析发现:KCNQ1OT1在胃癌中普遍高表达,且高表达KCNQ1OT1的胃癌病人预后不良,它与胃癌多种临床因素密切相关,尤其是与TP53的突变有明显的相关性,而且其表达与免疫细胞浸润明显相关;KCNQ1OT1在胃癌肿瘤细胞系中普遍高表达,敲低后可抑制胃癌肿瘤细胞的增殖能力,共表达网络分析发现,其表达与肿瘤代谢有密切的相关性;谷氨酰胺酶1(glutaminase 1, GLS1)在胃癌中普遍高表达,与预后不良密切相关,KCNQ1OT1与GLS1的表达具有明显的相关性,敲低KCNQ1OT1的表达可抑制GLS1 mRNA的表达,而过表达GLS1可以部分逆转敲低KCNQ1OT1造成的胃癌细胞增殖能力的下降,因此推测KCNQ1OT1可能通过GLS1调控胃癌肿瘤细胞的生长。本研究通过大数据及实验验证了KCNQ1OT1在胃癌中的表达及功能,提示KCNQ1OT1有可能通过调控谷氨酰胺代谢来促进了胃癌的发生发展,这为分子靶向治疗胃癌的临床研究提供了新的靶点和思路。 相似文献
5.
Glycogen storage disease type Ib (GSD-Ib) is caused by a deficiency in the glucose-6-phosphate transporter (G6PT). Sequence alignments identify a signature motif shared by G6PT and a family of transporters of phosphorylated metabolites. Two null signature motif mutations have been identified in the G6PT gene of GSD-Ib patients. In this study, we characterize the activity of seven additional mutants within the motif. Five mutants lack microsomal G6P uptake activity and one retains residual activity, suggesting that in G6PT the signature motif is a functional element required for microsomal glucose-6-phosphate transport. 相似文献
6.
HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease 总被引:4,自引:0,他引:4
Oberst MD Chen LY Kiyomiya K Williams CA Lee MS Johnson MD Dickson RB Lin CY 《American journal of physiology. Cell physiology》2005,289(2):C462-C470
Hepatocyte growth factor activator inhibitor-1 (HAI-1) was initially identified as cognate inhibitor of matriptase, a membrane-bound serine protease. Paradoxically, HAI-1 is also required for matriptase activation, a process that requires sphingosine 1-phosphate (S1P)-mediated translocation of the protease to cell-cell junctions in human mammary epithelial cells. In the present study, we further explored how HAI-1 regulates this protease. First, we observed that after S1P treatment HAI-1 was cotranslocated with matriptase to cell-cell junctions and that the cellular ratio of HAI-1 to matriptase was maintained during this process. However, when this ratio was changed by cell treatment with HAI-1 small interfering RNA or anti-HAI-1 MAb M19, spontaneous activation of matriptase occurred in the absence of S1P-induced translocation; S1P-induced matriptase activation was also enhanced. These results support a role for HAI-1 in protection of cell from uncontrolled matriptase activation. We next expressed matriptase, either alone or with HAI-1 in breast cancer cells that do not endogenously express either protein. A defect in matriptase trafficking to the cell surface occurred if wild-type matriptase was expressed in the absence of HAI-1; this defect appeared to result from matriptase toxicity to cells. Coexpression with matriptase of wild-type HAI-1, but not HAI-1 mutants altered in its Kunitz domain 1, corrected the trafficking defect. In contrast, catalytically defective matriptase mutants were normal in their trafficking in the absence of HAI-1. These results are also consistent with a role for HAI-1 to prevent inappropriate matriptase proteolytic activity during its protein synthesis and trafficking. Taken together, these results support multiple roles for HAI-1 to regulate matriptase, including its proper expression, intracellular trafficking, activation, and inhibition. protease-activated receptor-2; hepatocyte growth factor; urokinase; sphingosine 1-phosphate; Kunitz domain 相似文献
7.
In light of the growing incidence of oral cancer in Taiwan, this study is aimed at investigating the antitumor activity of 3,3'-diindolylmethane (DIM), an active metabolite of the phytochemical indole-3-carbinol (I3C), in oral squamous cell carcinoma (OSCC). DIM exhibited substantially higher antiproliferative potency than I3C in three OSCC cell lines with IC(50) values in SCC2095, SCC9, and SCC15 cells, respectively, of 22 versus 168μM, 25 versus 176μM, and 29versus 300μM. Flow cytometric analysis and Comet assay indicated that DIM suppressed the viability of SCC2095 cells by inducing apoptosis and G2/M arrest. Western blot analysis of various signaling markers revealed the ability of DIM to target pathways mediated by Akt, mitogen-activated protein (MAP) kinases, nuclear factor (NF)-κB, and p53, of which the concerted action underlined its antitumor efficacy. The concomitant inactivation of Akt and MAP kinases in response to DIM facilitated the dephosphorylation of the proapoptotic protein Bad at Ser-136 and Ser-112, respectively. Through endoplasmic reticulum (ER) stress, DIM stimulated the activation of p53 via Ser-15 phosphorylation, leading to increased expression of the BH3-only proapoptotic Bcl-2 members Puma and Noxa. Together, these changes decreased the mitochondrial threshold for apoptosis. G2/M arrest might be attributable to the suppressive effect of DIM on the expression of cyclin B1 and cdc25c. As many downstream effectors of the Akt-NF-κB pathway, including glycogen synthase kinase 3β, IκB kinase α, and cyclooxygenase-2, have been shown to promote oral tumorigenesis, the ability of DIM to inhibit this signaling axis underscores its chemopreventive potential in oral cancer. 相似文献
8.
Chang LY Lin YC Kang CW Hsu CY Chu YY Huang CT Day YJ Chen TC Yeh CT Lin CY 《Journal of immunology (Baltimore, Md. : 1950)》2012,189(2):567-574
CD103 is a marker for identification of effector/memory regulatory T cells (Tregs). CD103(+) Tregs are potent suppressors of tissue inflammation in several infectious diseases, autoimmune diseases, and cancers. However, the underlying mechanisms for this potent suppression ability remain unclear. The current study was designed to clarify this issue. Unexpectedly, we found both CD103(+) and CD103(-) Tregs had similar suppression capacity in vitro. We then chose a murine tumor model for investigation of the in vivo behavior of these Tregs. The suppression ability in vivo against the anti-tumor ability of CD8(+) T cells was restricted to CD103(+) Tregs although both Tregs had equal in vitro suppression ability. In addition, CD103(+) Tregs expressed significantly higher levels of CCR5 than those of CD103(-) Tregs and accumulated more in tumors than did CD103(-) Tregs. Furthermore, blockade of CCR5 signaling, either by CCR5(-/-)CD103(+) Tregs or by CCL5 knockdown tumor, could reduce the migration of CD103(+) Tregs into tumors and impair their in vivo suppression ability. In conclusion, these results indicate that the potent in vivo suppression ability of CD103(+) Tregs is due to the tissue-migration ability through CCR5 expression. 相似文献
9.
Ji-Yuan Han Hui Wang Yun-Tao Xie Yan Li Li-Yuan Zheng Yuan Ruan Ai-Ping Song Xin-Xia Tian Wei-Gang Fang 《PloS one》2012,7(11)
Background
Somatic alterations of cyclin-dependent kinase 2 (CDK2)-cyclin E complex have been shown to contribute to breast cancer (BC) development and progression. This study aimed to explore the effects of single nucleotide polymorphisms (SNPs) in CDK2 and CCNE1 (a gene encoding G1/S specific cyclin E1 protein, formerly called cyclin E) on BC risk, progression and survival in a Chinese Han population.Methodology/Principal Findings
We herein genotyped 6 haplotype-tagging SNPs (htSNPs) of CCNE1 and 2 htSNPs of CDK2 in 1207 BC cases and 1207 age-matched controls among Chinese Han women, and then reconstructed haplotype blocks according to our genotyping data and linkage disequilibrium status of these htSNPs. For CCNE1, the minor allele homozygotes of three htSNPs were associated with BC risk (rs3218035: adjusted odds ratio [aOR] = 3.35, 95% confidence interval [CI] = 1.69–6.67; rs3218038: aOR = 1.81, 95% CI = 1.22–2.70; rs3218042: aOR = 2.64, 95% CI = 1.31–5.34), and these three loci showed a dose-dependent manner in increasing BC risk (P trend = 0.0001). Moreover, the 5-SNP haplotype CCGTC, which carried none of minor alleles of the 3 at-risk SNPs, was associated with a favorable event-free survival (hazard ratio [HR] = 0.53, 95% CI = 0.32–0.90). Stratified analysis suggested that the minor-allele homozygote carriers of rs3218038 had a worse event-free survival among patients with aggressive tumours (in tumour size>2 cm group: HR = 2.06, 95% CI = 1.06–3.99; in positive lymph node metastasis group: HR = 2.41, 95% CI = 1.15–5.03; in stage II–IV group: HR = 2.03, 95% CI = 1.09–3.79). For CDK2, no significant association was found.Conclusions/Significance
This study indicates that genetic variants in CCNE1 may contribute to BC risk and survival in Chinese Han population. They may become molecular markers for individual evaluation of BC susceptibility and prognosis. Nevertheless, further validation studies are needed. 相似文献10.
SP Yeh YM Liao WJ Lo CL Lin LY Bai CY Lin CY Hsieh YC Chang YT Huang CF Chiu 《PloS one》2012,7(9):e44416